Clinical characteristics and prognosis of non-small cell lung cancer patients with liver metastasis: A population-based study

被引:6
|
作者
Wang, Jun-Feng [1 ]
Lu, Hong-Di [1 ]
Wang, Ying [1 ]
Zhang, Rui [1 ]
Li, Xiang [2 ]
Wang, Sheng [1 ,3 ]
机构
[1] Jilin Prov Tumor Hosp, Dept Thorac Oncol 1, Changchun 130021, Jilin, Peoples R China
[2] Jilin Prov Tumor Hosp, Big Data Ctr Clin Res, Changchun 130021, Jilin, Peoples R China
[3] Jilin Prov Tumor Hosp, Dept Thorac Oncol 1, 1018 Huguang St, Changchun 130021, Jilin, Peoples R China
关键词
Non-small cell lung cancer; Liver metastasis; Nomogram; Risk classification system; SURVIVAL; GENDER; EPIDEMIOLOGY; NOMOGRAM; SURGERY; THERAPY; NSCLC;
D O I
10.12998/wjcc.v10.i30.10882
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND The presence of liver metastasis (LM) is an independent prognostic factor for shorter survival in non-small cell lung cancer (NSCLC) patients. The median overall survival of patients with involvement of the liver is less than 5 mo. At present, identifying prognostic factors and constructing survival prediction nomogram for NSCLC patients with LM (NSCLC-LM) are highly desirable. AIM To build a forecasting model to predict the survival time of NSCLC-LM patients. METHODS Data on NSCLC-LM patients were collected from the Surveillance, Epidemiology, and End Results database between 2010 and 2018. Joinpoint analysis was used to estimate the incidence trend of NSCLC-LM. Kaplan-Meier curves were constructed to assess survival time. Cox regression was applied to select the independent prognostic predictors of cancer-specific survival (CSS). A nomogram was established and its prognostic performance was evaluated. RESULTS The age-adjusted incidence of NSCLC-LM increased from 22.7 per 1000000 in 2010 to 25.2 in 2013, and then declined to 22.1 in 2018. According to the multivariable Cox regression analysis of the training set, age, marital status, sex, race, histological type, T stage, metastatic pattern, and whether the patient received chemotherapy or not were identified as independent prognostic factors for CSS (P < 0.05) and were further used to construct a nomogram. The C-indices of the training and validation sets were 0.726 and 0.722, respectively. The results of decision curve analyses (DCAs) and calibration curves showed that the nomogram was well-discriminated and had great clinical utility. CONCLUSION We designed a nomogram model and further constructed a novel risk classification system based on easily accessible clinical factors which demonstrated excellent performance to predict the individual CSS of NSCLC-LM patients.
引用
收藏
页码:10882 / 10895
页数:14
相关论文
共 50 条
  • [1] Clinical characteristics and prognosis of non-small cell lung cancer patients with liver metastasis:A population-based study
    Jun-Feng Wang
    Hong-Di Lu
    Ying Wang
    Rui Zhang
    Xiang Li
    Sheng Wang
    World Journal of Clinical Cases, 2022, 10 (30) : 10882 - 10895
  • [2] A population-based study of gefitinib in patients with non-small cell lung cancer
    Kenji Hayashibara
    Hiroaki Satoh
    Yoko Shinohara
    Masaharu Inagaki
    Takayuki Kaburagi
    Toshio Hashimoto
    Koichi Kurishima
    Hiroichi Ishikawa
    Hideo Ichimura
    Takeshi Nawa
    Yasunori Funayama
    Takeshi Matsumura
    Katsunori Kagohashi
    Takeshi Endo
    Kinya Furukawa
    Koji Kishi
    Masaaki Sumi
    Koichi Kamiyama
    Shigemi Ishikawa
    Medical Oncology, 2009, 26 : 222 - 227
  • [3] A population-based study of gefitinib in patients with non-small cell lung cancer
    Hayashibara, Kenji
    Satoh, Hiroaki
    Shinohara, Yoko
    Inagaki, Masaharu
    Kaburagi, Takayuki
    Hashimoto, Toshio
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Ichimura, Hideo
    Nawa, Takeshi
    Funayama, Yasunori
    Matsumura, Takeshi
    Kagohashi, Katsunori
    Endo, Takeshi
    Furukawa, Kinya
    Kishi, Koji
    Sumi, Masaaki
    Kamiyama, Koichi
    Ishikawa, Shigemi
    MEDICAL ONCOLOGY, 2009, 26 (02) : 222 - 227
  • [4] Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study
    Lofling, Lukas
    Karimi, Annette
    Sandin, Fredrik
    Bahmanyar, Shahram
    Kieler, Helle
    Lambe, Mats
    Lamberg, Kristina
    Wagenius, Gunnar
    ACTA ONCOLOGICA, 2019, 58 (11) : 1618 - 1627
  • [5] Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer
    Shiroyama, Takayuki
    Suzuki, Hidekazu
    Tamiya, Motohiro
    Tamiya, Akihiro
    Tanaka, Ayako
    Okamoto, Norio
    Nakahama, Kenji
    Taniguchi, Yoshihiko
    Isa, Shun-Ichi
    Inoue, Takako
    Imamura, Fumio
    Atagi, Shinji
    Hirashima, Tomonori
    ANTICANCER RESEARCH, 2018, 38 (08) : 4723 - 4729
  • [6] Prognosis of non-small cell lung cancer patients with brain metastasis
    Ohhara, Yoshihito
    Isobe, Hiroshi
    Sato, Toshitaka
    Ito, Kenichiro
    Fuke, Satoshi
    Kojima, Tetsuya
    Saito, Hiroshi
    Nishiura, Yoichi
    ANNALS OF ONCOLOGY, 2015, 26 : 106 - 106
  • [7] A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer
    Furukawa, Kinya
    Ishida, Junzo
    Inagaki, Masaharu
    Takabe, Kazuhiko
    Ishikawa, Shigemi
    Sakai, Mitsuaki
    Ichimura, Hideo
    Kamiyama, Koichi
    Kaburagi, Takayuki
    Hayashihara, Kenji
    Kishi, Koji
    Saito, Makoto
    Satoh, Hiroaki
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (01) : 53 - 59
  • [8] Investigation of the non-small cell lung cancer patients with uncertain resection: A population-based study
    Wang, Xun
    Cai, Jing-Sheng
    Yang, Fan
    LUNG CANCER, 2022, 171 : 47 - 55
  • [9] Investigation of the non-small cell lung cancer patients with bronchus involvements: A population-based study
    Wang, Gang
    Ye, Yong-Qiang
    Xie, Bao-Long
    Lai, Xiang-Min
    Zhong, Sheng-Peng
    CLINICAL RESPIRATORY JOURNAL, 2023, 17 (09): : 941 - 950
  • [10] Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study
    Verleye, L.
    De Gendt, C.
    Vrijens, F.
    Schillemans, V.
    Camberlin, C.
    Silversmit, G.
    Stordeur, S.
    Van Eycken, E.
    Dubois, C.
    Robays, J.
    Wauters, I.
    Van Meerbeeck, J. P.
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (01)